Vireo Health to Report Second Quarter 2019 Results on August 29, 2019

VIEW ALL NEWS

Goodness Growth Holdings Opens Two Additional Green Goods® Cannabis Dispensaries in New Mexico

VIEW ALL NEWS

Vireo Health Affiliate Given Green Light to Operate Medical Cannabis Processing Facility in Ohio

Ohio Medical Solutions will manufacture and wholesale Vireo-branded medical cannabis products to third-party dispensaries throughout the Buckeye State

MINNEAPOLIS, Aug. 15, 2019 /PRNewswire/ — Vireo Health International, Inc. (“Vireo” or the “Company”) (CNSX: VREO, OTCQX: VREOF), a leading physician-led, science-focused multi-state cannabis company, today announced that the Company’s affiliate, Ohio Medical Solutions (“OMS”), was granted a Certificate of Operation by the Ohio Department of Commerce. OMS, which will begin operating immediately, was previously awarded a provisional processing license.

Vireo Logo (PRNewsfoto/Vireo Health, Inc.)

OMS is now permitted to purchase plant material from licensed cultivators, manufacture a wide variety of Vireo-branded pharmaceutical-grade cannabis products, and wholesale these products to third-party dispensaries throughout the state of Ohio.

“We are delighted that Ohio Medical Solutions will begin manufacturing Vireo products for the benefit of Ohio patients,” said Chief Executive Officer, Kyle Kingsley, M.D. “The City of Akron has been great to us and as our business grows, we look forward to continuing to create new jobs and make a positive impact on the local economy.”

Located in a former factory building that had fallen into disuse and disrepair, the Company’s 11,500 square-foot facility, in Akron, Ohio has been transformed, through a multi-million-dollar investment, into a state-of-the-art pharmaceutical manufacturing facility. The renovated facility features new building systems, a new roof, complete interior redesign, and the installation of a best-in-class security system and fence.

“I am honored to serve as General Manager and lead this facility,” said Marie Walchalk, OMS General Manager. “As a life-long Ohioan I have personally witnessed too many manufacturing jobs leave our State and it’s great to be part of an industry adding new good-paying local jobs.”

Ohio’s Medical Marijuana Bill (HB 523) was signed into law on June 8, 2016 by Governor Kasich. The State’s medical marijuana program is rapidly expanding. Sales of medical marijuana officially began on January 16, 2019. There are now 527 certified physicians and 25 active dispensaries serving the State’s 53,082 registered patients and almost 4,000 registered caregivers.

About Vireo Health International, Inc.

Vireo Health International, Inc.’s mission is to build the cannabis company of the future by bringing the best of medicine, engineering and science to the cannabis industry.  Vireo’s physician-led team of more than 300 employees provides best-in-class cannabis products and customer experience. Vireo cultivates cannabis in environmentally friendly greenhouses, manufactures pharmaceutical-grade cannabis extracts, and sells its products at both company-owned and third-party dispensaries. The Company currently is licensed in eleven markets including Arizona, Maryland, Massachusetts, Minnesota, New Mexico, New York, Nevada, Ohio, Pennsylvania, Puerto Rico, and Rhode Island.  For more information about the company, please visit www.vireohealth.com.

Contact Information 

Investor Inquiries
Sam Gibbons
Vice President, Investor Relations
samgibbons@vireohealth.com
(612) 314-8995

Media Inquiries
Albe Zakes
Vice President, Corporate Communications
albezakes@vireohealth.com
(267) 221-4800

This news release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

Forward-Looking Statement Disclosure

This news release contains forward-looking information within the meaning of applicable securities laws, based on current expectations. Generally, any statements that are not historical facts may contain forward-looking information, and forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “look forward to”, “budget” “scheduled”, “estimates”, “forecasts”, “will continue”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or indicates that certain actions, events or results “may”, “could”, “would”, “might” or “will be” taken, “occur” or “be achieved.” Forward looking information may include, without limitation, statements regarding the operations, business, financial condition, expected financial results, performance, prospects, opportunities, priorities, targets, goals, ongoing objectives, milestones, strategies and outlook of Vireo, and includes statements about, among other things, future developments, the future operations, potential market opportunities, strengths and strategy of the Company. Forward-looking information is provided for the purpose of presenting information about management’s current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. These statements should not be read as guarantees of future performance or results. These statements are based upon certain material factors, assumptions and analyses that were applied in drawing a conclusion or making a forecast or projection, including Vireo’s experience and perceptions of historical trends, current conditions and expected future developments, as well as other factors that are believed to be reasonable in the circumstances.

Examples of the assumptions underlying the forward-looking statements contained herein include, but are not limited to those related to: the achievement of goals, the closing of acquisitions, obtaining of necessary permits and governmental approvals, future market positioning, as well as expectations regarding availability of equipment, skilled labor and services needed for cannabis operations, intellectual property rights,  development, operating or regulatory risks, trends and developments in the cannabis industry, business strategy and outlook, expansion and growth of business and operations, the timing and amount of capital expenditures; future exchange rates; the impact of increasing competition; conditions in general economic and financial markets; access to capital; future operating costs; government regulations, including future legislative and regulatory developments involving medical and recreational marijuana and the timing thereto; receipt of appropriate and necessary licenses in a timely manner; the effects of regulation by governmental agencies; the anticipated changes to laws regarding the recreational use of cannabis; the demand for cannabis products and corresponding forecasted increase in revenues; and the size of the medical marijuana market and the recreational marijuana market.

Although such statements are based on management’s reasonable assumptions at the date such statements are made, there can be no assurance that it will be completed on the terms described above and that such forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such forward-looking information. Accordingly, readers should not place undue reliance on the forward-looking information. Vireo assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by applicable law.

By its nature, forward-looking information is subject to risks and uncertainties, and there are a variety of material factors, many of which are beyond the control of the Company and that may cause actual outcomes to differ materially from those discussed in the forward-looking statements. These factors include, but are not limited to: denial or delayed receipt of all necessary consents and approvals; need for additional capital expenditures; increased costs and timing of operations; unexpected costs associated with environmental liabilities; requirements for additional capital; reduced future prices of cannabis; failure of plant, equipment or processes to operate as anticipated; accidents, labour disputes and other risks of the cannabis industry; delays in obtaining governmental approvals, permits or financing or in the completion of development or construction activities; title disputes; claims limitations on insurance coverage; risks related to the integration of acquisitions; fluctuations in the spot and forward price of certain commodities (such as diesel fuel and electricity); changes in national and local government legislation, taxation, controls, regulations and political or economic developments in the countries where the Company may carry on business in the future;  liabilities inherent in cannabis operations;  risks relating to medical and recreational cannabis; cultivation, extraction and distribution problems; competition for, among other things, capital, licences and skilled personnel;  risks relating to the timing of legalization of recreational cannabis; changes in laws relating to the cannabis industry; and management’s success in anticipating and managing the foregoing factors.

 

CisionView original content to download multimedia:http://www.prnewswire.com/news-releases/vireo-health-affiliate-given-green-light-to-operate-medical-cannabis-processing-facility-in-ohio-300902399.html

SOURCE Vireo Health International, Inc.

Vireo Health to Present at the 39th Annual Canaccord Genuity Growth Conference

MINNEAPOLIS, Aug. 6, 2019 /PRNewswire/ — Vireo Health International, Inc. (“Vireo” or the “Company”) (CNSX: VREO; OTCQX: VREOF), a leading physician-led, science-focused, multi-state cannabis company, today announced its participation at the 39th Annual Canaccord Genuity Growth Conference in Boston on August 8, 2019.

Vireo Logo (PRNewsfoto/Vireo Health, Inc.)

Chief Executive Officer Kyle Kingsley, M.D., will present and meet with investors at the conference. Dr. Kingsley’s presentation will begin at approximately 8:00 a.m. ET (7:00 a.m. CT). An electronic copy of Dr. Kingsley’s presentation will be available in the investor relations section of Vireo’s website.

The Canaccord Genuity Growth Conference has become one of the industry’s premier investment industry conferences for companies and investors focused on growth. During this two-day event, leading companies and investors in the global growth universe will come together to share knowledge, discuss emerging trends, build relationships, identify opportunities, and ignite global ideas for growth. Investors interested in meeting with Vireo management at this event should contact their Canaccord representative.

About Vireo Health International, Inc.

Vireo Health International, Inc.’s mission is to build the cannabis company of the future by bringing the best of medicine, engineering and science to the cannabis industry. Vireo’s physician-led team of more than 350 employees provides best-in-class cannabis products and customer experience. Vireo cultivates cannabis in environmentally-friendly greenhouses, manufactures pharmaceutical-grade cannabis extracts, and sells its products at both company-owned and third-party dispensaries. The Company is currently licensed in eleven markets including Arizona, Maryland, Massachusetts, Minnesota, Nevada, New Mexico, New York, Ohio, Pennsylvania, Puerto Rico, and Rhode Island. For more information about the company, please visit www.vireohealth.com.

Contact Information 

Investor Inquiries
Sam Gibbons
Vice President, Investor Relations
samgibbons@vireohealth.com
(612) 314-8995

Media Inquiries
Albe Zakes
Vice President, Corporate Communications
albezakes@vireohealth.com
(267) 221-4800

 

CisionView original content to download multimedia:http://www.prnewswire.com/news-releases/vireo-health-to-present-at-the-39th-annual-canaccord-genuity-growth-conference-300897023.html

SOURCE Vireo Health International, Inc.

OTC Markets Group Welcomes Vireo Health International Inc. to OTCQX

NEW YORK, Aug. 2, 2019 /PRNewswire/ — OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced Vireo Health International Inc. (CSE: VREO; OTCQX: VREOF), a leading cannabis company whose mission is to bring the best of medicine, engineering and science to the cannabis industry, has qualified to trade on the OTCQX® Best Market.

Vireo Health International begins trading today on OTCQX under the symbol “VREOF.”  U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com.

“We are pleased to welcome Vireo Health International to the OTCQX Best Market,” said Jason Paltrowitz, EVP of Corporate Services at OTC Markets Group. “Along with their recent listing on the Canadian Securities Exchange in March and subsequent M&A transactions, trading on the OTCQX Market in the U.S. will enable Vireo Health to build stronger visibility and awareness across North America and provide investors with transparent trading. We look forward to supporting the company in the U.S. public market.”

MCAP LLC acted as Vireo Health International’s OTCQX sponsor.

About Vireo Health International Inc.
Vireo’s mission is to build the cannabis company of the future by bringing the best of medicine, engineering and science to the cannabis industry. The company’s physician-led team of more than 300 employees provides best-in-class cannabis products and customer experience. Vireo cultivates cannabis in environmentally-friendly greenhouses, manufactures pharmaceutical-grade cannabis extracts, and sells its products at both company-owned and third-party dispensaries. The company is currently licensed in ten states including Arizona, Maryland, Massachusetts, Minnesota, Nevada, New Mexico, New York, Ohio, Pennsylvania, and Rhode Island.

About OTC Markets Group Inc.
OTC Markets Group Inc. (OTCQX: OTCM) operates the OTCQX® Best Market, the OTCQB® Venture Market and the Pink® Open Market for 10,000 U.S. and global securities.  Through OTC Link® ATS and OTC Link ECN, we connect a diverse network of broker-dealers that provide liquidity and execution services.  We enable investors to easily trade through the broker of their choice and empower companies to improve the quality of information available for investors.

To learn more about how we create better informed and more efficient markets, visit www.otcmarkets.com.

OTC Link ATS and OTC Link ECN are SEC regulated ATSs, operated by OTC Link LLC, member FINRA/SIPC.

Subscribe to the OTC Markets RSS Feed

Media Contact:
OTC Markets Group Inc., +1 (212) 896-4428, media@otcmarkets.com

Vireo Health Contacts:

Investor Inquiries
Sam Gibbons
samgibbons@vireohealth.com
(612) 314-8995

Media Inquiries
Albe Zakes
albezakes@vireohealth.com
(267) 221-4800

Vireo Health Subordinate Voting Shares Approved for Inclusion on the OTCQX® Best Market

Shares will begin trading under ticker symbol “VREOF” on August 2

MINNEAPOLIS, Aug. 1, 2019 /PRNewswire/ — Vireo Health International, Inc. (“Vireo” or the “Company”) (CNSX: VREO; OTCQX: VREOF), a leading physician-led, science-focused, multi-state cannabis company, today announced that it has qualified to trade on the OTCQX® Best Market. Vireo will begin trading on August 2 on OTCQX under the symbol “VREOF.”

Vireo Logo (PRNewsfoto/Vireo Health, Inc.)

Vireo first went public earlier this year, when it began trading on the Canadian Securities Exchange under the stock symbol “VREO”.

U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the Company at www.otcmarkets.com/stock/VREOF/overview. MCAP LLC acted as Vireo Health International’s OTCQX sponsor.

About Vireo Health International, Inc.
Vireo Health International, Inc.’s mission is to build the cannabis company of the future by bringing the best of medicine, engineering and science to the cannabis industry. Vireo’s physician-led team of more than 350 employees provides best-in-class cannabis products and customer experience. Vireo cultivates cannabis in environmentally-friendly greenhouses, manufactures pharmaceutical-grade cannabis extracts, and sells its products at both company-owned and third-party dispensaries. The Company is currently licensed in eleven markets including Arizona, Maryland, Massachusetts, Minnesota, Nevada, New Mexico, New York, Ohio, Pennsylvania, Puerto Rico, and Rhode Island. For more information about the company, please visit www.vireohealth.com.

About OTC Markets Group Inc.
OTC Markets Group Inc. operates the OTCQX® Best Market, the OTCQB® Venture Market and the Pink® Open Market for 10,000 U.S. and global securities.  Through OTC Link® ATS and OTC Link ECN, we connect a diverse network of broker-dealers that provide liquidity and execution services.  We enable investors to easily trade through the broker of their choice and empower companies to improve the quality of information available for investors. To learn more about how we create better informed and more efficient markets, visit www.otcmarkets.com.

OTC Link ATS and OTC Link ECN are SEC regulated ATSs, operated by OTC Link LLC, member FINRA/SIPC.

Contact Information 

Investor Inquiries
Sam Gibbons
Vice President, Investor Relations
samgibbons@vireohealth.com
(612) 314-8995

Media Inquiries
Albe Zakes
Vice President, Corporate Communications
albezakes@vireohealth.com   
(267) 221-4800

 

CisionView original content to download multimedia:http://www.prnewswire.com/news-releases/vireo-health-subordinate-voting-shares-approved-for-inclusion-on-the-otcqx-best-market-300895343.html

SOURCE Vireo Health International, Inc.

Vireo Health Files Patent for Multichannel Vaporizer

Company is developing a vaporizer that allows consumers to customize their experience by utilizing multiple cartridges in one device

MINNEAPOLIS, July 25, 2019 /PRNewswire/ — Vireo Health International, Inc. (“Vireo” or the “Company”) (CSE: VREO), a leading physician-led, science-focused multi-state cannabis company, today announced that the Company filed a patent application with United States Patent and Trademark Office (“USPTO”) for a multichannel vaporizer designed to hold at least two vaporizer cartridges. The device will allow a user to adjust the mixture of vapor coming from each cartridge using a simple interface.

Vireo Logo (PRNewsfoto/Vireo Health, Inc.)

“Vireo Health is committed to helping consumers find their ‘cannabis sweet spot’ whether they are a connoisseur or a first-time user,” said Founder and CEO Kyle Kingsley, M.D. “When developed, in addition to potential medical benefits, we expect that the multichannel vaporizer will allow consumers to control and adjust their own experience or even create their own custom blends of different strains, terpene profiles, and flavors.”

Currently, if a consumer or patient wants to use more than one vaporizer formulation, he or she needs to purchase a separate vaporizer cartridge for each formulation. For example, if a user wanted the full spectrum of THC to CBD ratios that Vireo offers, the patient would have to purchase five different cartridges. The user would also need to purchase a separate battery for each cartridge or change out the cartridges every time he or she wanted to use a different formulation.

The multichannel vaporizer will be a single device that will allow a user to carefully change and control the desired effect for every inhalation. In one application­­ of the invention, the vaporizer would house a separate THC cartridge and CBD cartridge, thus enabling the user to adjust the THC to CBD ratio of the vapor to his or her preference in real time.

About Vireo Health International, Inc.

Vireo Health International, Inc.’s mission is to build the cannabis company of the future by bringing the best of medicine, engineering and science to the cannabis industry.  Vireo’s physician-led team of more than 350 employees provides best-in-class cannabis products and customer experience. Vireo cultivates cannabis in environmentally friendly greenhouses, manufactures pharmaceutical-grade cannabis extracts, and sells its products at both company-owned and third-party dispensaries. The Company currently is licensed in eleven markets including Arizona, Maryland, Massachusetts, Minnesota, Nevada, New Mexico, New York, Ohio, Pennsylvania, Puerto Rico, and Rhode Island.  For more information about the company, please visit www.vireohealth.com.

Contact Information

Media Inquiries
Albe Zakes
Vice President, Corporate Communications
albezakes@vireohealth.com
(267) 221-4800

Investor Inquiries
Sam Gibbons
Vice President, Investor Relations
samgibbons@vireohealth.com
(612) 314-8995

 

CisionView original content to download multimedia:http://www.prnewswire.com/news-releases/vireo-health-files-patent-for-multichannel-vaporizer-300890975.html

SOURCE Vireo Health International, Inc.

Vireo Health CEO Kyle Kingsley, M.D. responds to U.S. Senate Committee on Banking, Housing and Urban Affairs Hearing on Challenges for Cannabis and Banking

VIEW ALL NEWS

Vireo Health Launches New York’s First Same-Day Marijuana Delivery Service

With More than 25,000 Home Deliveries – Company Now Offers Free Same-Day Option

NEW YORK, July 16, 2019 /PRNewswire/ — Vireo Health of New York (“Vireo” or the “Company”), a subsidiary of Vireo Health International (CSE: VREO), a leading physician-led, science-focused multi-state cannabis company, today announced that patients living in the New York City metro area, Westchester County, and Nassau County now have access to free, same-day marijuana delivery.

Vireo Logo (PRNewsfoto/Vireo Health, Inc.)

Launched in April 2017, Vireo’s medical marijuana home delivery service has rapidly expanded. Since its inception, the Company has made more than 25,000 home deliveries to patients. With over 1,000 Google reviews with an average 4.9 out of 5 star rating, it is now the first company in New York to offer a free same-day delivery option.

“Our same-day home delivery service is designed to match the convenience that New Yorkers have become accustomed to in the era of Amazon, Uber and Seamless,” said Founder and Chief Executive Officer, Kyle Kingsley, M.D.  “The growing popularity of our home delivery service has allowed us to achieve the economies of scale necessary to offer same-day delivery throughout the Greater New York City area.”

Vireo’s home delivery service was designed by a team of security experts, pharmacists, and health-care providers. “As a physician-led company, our goal is to provide safe and effective products in a trusted and supportive environment, and nothing is safer than one’s own home. We want to ensure that all our patients do not feel stigmatized and can receive the highest quality service and products with the convenience they deserve,” said Stephen Dahmer, M.D., Chief Medical Officer of Vireo Health.

Patients who place orders by 12:00 p.m. EDT will be eligible to receive free same-day delivery. Payment for deliveries can be made using CanPay, a cannabis debit payment app available on iPhone and Android devices. More information is available online at www.vireohealth.com/ny/delivery.

About Vireo Health International, Inc.
Vireo Health International, Inc.’s mission is to build the cannabis company of the future by bringing the best of medicine, engineering and science to the cannabis industry.  Vireo’s physician-led team of more than 350 employees provides best-in-class cannabis products and customer experience. Vireo cultivates cannabis in environmentally friendly greenhouses, manufactures pharmaceutical-grade cannabis extracts, and sells its products at both company-owned and third-party dispensaries. The Company currently is licensed in eleven markets including Arizona, Maryland, Massachusetts, Minnesota, New Mexico, New York, Ohio, Pennsylvania, Puerto Rico, and Rhode Island.  For more information about the company, please visit www.vireohealth.com.

Contact Information

Media Inquiries
Albe Zakes
Vice President, Corporate Communications
albezakes@vireohealth.com
(267) 221-4800

CisionView original content to download multimedia:http://www.prnewswire.com/news-releases/vireo-health-launches-new-yorks-first-same-day-marijuana-delivery-service-300885679.html

SOURCE Vireo Health International, Inc.

Vireo Health Announces Inclusion in Horizons Marijuana Index ETFs

MINNEAPOLIS, June 27, 2019 /PRNewswire/ — Vireo Health International, Inc. (“Vireo” or the “Company”) (CSE: VREO; OTCQX: VREOF), a leading science-focused, multi-state cannabis company, today announced that its shares have been included in the Horizons US Marijuana Index ETF (HMUS) and the Horizons Emerging Marijuana Growers Index ETF (HMJR).

Vireo Logo (PRNewsfoto/Vireo Health, Inc.)

The Horizons US Marijuana Index (HMUS) was the first of its kind and seeks to track the price movements of a portfolio of North American publicly listed companies with significant business activities in the United States marijuana or hemp industries. Stocks must meet certain requirements to be included in this ETF. A company must be listed on an US or Canadian exchange, represent significant exposure in the hemp and marijuana industries, have a market capitalization greater than CAD$75M, a stock price greater than CAD$0.25, and have a 30 day average daily trading volume of greater than CAD$100,000. Stocks in this ETF are rebalanced quarterly so that no single stock holds more than 10.0 percent of the weight in the index.

The Horizons Emerging Marijuana Growers Index (HMJR) is designed to provide exposure to the performance of a basket of primarily North American publicly listed small-capitalization companies primarily involved in the cultivation, production and/or distribution of marijuana. Stocks must meet certain requirements to be included in this ETF. A company must be listed on a regulated stock exchange in a developed market; be a cultivator, producer, and/or distributor of marijuana or cannabis; and have a market capitalization greater than CAD$50M. Stocks in this ETF are rebalanced quarterly so that no single stock holds more than eight percent of the weight in the index.

About Vireo Health International, Inc.
Vireo Health International, Inc.’s mission is to build the cannabis company of the future by bringing the best of medicine, engineering and science to the cannabis industry. Vireo’s physician-led team of more than 350 employees provides best-in-class cannabis products and customer experience. Vireo cultivates cannabis in environmentally-friendly greenhouses, manufactures pharmaceutical-grade cannabis extracts, and sells its products at both company-owned and third-party dispensaries. The Company is currently licensed in eleven states and territories: Arizona, Maryland, Massachusetts, Minnesota, Nevada, New Mexico, New York, Ohio, Pennsylvania, Puerto Rico and Rhode Island. For more information about the company, please visit www.vireohealth.com.

Contact Information 

Investor Inquiries
Sam Gibbons
Vice President, Investor Relations
samgibbons@vireohealth.com
(612) 314-8995

Media Inquiries
Albe Zakes
Vice President, Corporate Communications
albezakes@vireohealth.com
(267) 221-4800

CisionView original content to download multimedia:http://www.prnewswire.com/news-releases/vireo-health-announces-inclusion-in-horizons-marijuana-index-etfs-300876102.html

SOURCE Vireo Health International, Inc.